PDS Biotechnology Corp
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(26,932,586) | $(29,658,032) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,948,396 | 5,204,005 |
| Issuance of shares in consulting agreements | 203,501 | 267,000 |
| Amortization of debt discount | 1,079,427 | 859,135 |
| Loss on retirement of debt | 752,838 | - |
| Depreciation expense | 16,377 | 15,654 |
| Finance lease depreciation expense | 29,010 | 29,010 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other assets | (4,883,470) | 114,499 |
| Accounts payable | 3,496,060 | (5,681,904) |
| Accrued expenses | (758,980) | 2,054,849 |
| Net cash used in operating activities | (24,049,427) | (26,795,784) |
| Cash flows from investing activities: | ||
| Purchase of equipment | - | (29,000) |
| Net cash used in investing activities | - | (29,000) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of pre-funded warrants | 1,009,969 | - |
| Proceeds from issuance of warrants | 2,150,771 | - |
| Proceeds from exercise of pre-funded warrants | 94 | - |
| Proceeds from exercise of stock options | - | 629,591 |
| Payments of finance lease obligations | (45,313) | (41,366) |
| Loan principal payments | (5,166,667) | - |
| Loan repayment | (18,645,833) | - |
| Net proceeds from issuance of loan | 19,237,884 | - |
| Proceeds from issuance of common stock from the Sales Agreement, net | 3,023,409 | 19,427,294 |
| Proceeds from issuance of common stock, net of issuance costs | 6,994,174 | - |
| Net cash provided by financing activities | 8,558,488 | 20,015,519 |
| Net decrease in cash and cash equivalents | (15,490,939) | (6,809,265) |
| Cash and cash equivalents at beginning of period | 41,689,591 | 56,560,517 |
| Cash and cash equivalents at the end of period | $26,198,652 | $49,751,252 |
| Supplemental information of cash and non-cash transactions: | ||
| Cash paid for interest | $2,284,553 | $2,721,354 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.